GlycOBI® Advances Bispecific and Dual Payload ADC Development
OBI Demonstrates Innovations at the Novel Conjugates Summit in Boston

The highly anticipated 4th Novel Conjugates Summit, drawing global industry attention, took place in Boston, USA, from 3/25 to 3/27. OBI Pharma (4174.TWO) showcased its innovative Antibody-Drug Conjugate (ADC) technology platform, GlycOBI®, and emphasized its unique strengths and versability in the development of bispecific (BsADCs) and dual payload ADCs.